People who sleep about seven hours a night age more slowly across multiple organs than those who sleep significantly more or less, according to a study that drew on data from roughly half a million participants in the UK Biobank. The finding, published in Nature by the MULTI Consortium, adds biological-clock evidence to a body of research that had already linked the same sleep window to lower death rates. For the tens of millions of American adults who routinely fall short of seven hours, the results sharpen a simple but consequential question: could shifting sleep duration by even 30 or 60 minutes slow the wear on hearts, kidneys, and brains over decades?
Why the seven-hour sleep target matters right now
The MULTI Consortium mapped self-reported and device-measured sleep duration against multi-organ, multi-omics biological ageing clocks and found a clear U-shaped pattern. Both short and long sleep were tied to a higher biological ageing burden, with the lowest ageing-clock readings clustering around six to eight hours and centering near seven, according to the Nature study. That means sleeping five hours carried a similar penalty to sleeping nine or ten, a pattern that challenges the common assumption that more rest is always better.
The ageing-clock approach goes beyond traditional mortality tracking. Rather than waiting years to count deaths, researchers used molecular markers from blood, metabolic panels, and organ-specific biomarkers to estimate how fast tissues deteriorate. The result is a more granular picture of what sleep duration does to the body before disease or death occurs. The U.S. Centers for Disease Control and Prevention recommends at least seven hours of sleep per day for adults, a threshold that aligns with the new biological data but was set primarily on the basis of earlier epidemiological studies and expert consensus. The tension between “at least seven” and “about seven” is not trivial: the Nature findings suggest that consistently overshooting the mark also carries measurable biological costs.
A separate line of evidence strengthens the case. A prospective cohort study of 90,398 UK Biobank participants that used wrist-worn accelerometers to objectively measure sleep found that device-measured duration and efficiency were jointly associated with all-cause and cause-specific mortality. The sweet spot for survival, once again, hovered near seven hours. Because accelerometers bypass the well-known inaccuracies of self-reported sleep, this study offers a harder data point than questionnaire-based work alone.
Three converging datasets and what they measured
The UK Biobank recruited 503,317 participants between 2006 and 2010, creating one of the largest biomedical databases in the world. Its scale is what allows researchers to detect small but meaningful differences in ageing rates across sleep-duration bands. The MULTI Consortium’s analysis layered multiple biological clocks on top of that cohort, producing what Nature News described as a sleep chart of biological ageing in middle and late life. The study framed the six-to-eight-hour window, roughly seven hours, as the range tied to the slowest ageing progression.
A third study, published in the journal Sleep, examined actigraphy-measured sleep duration, continuity, and timing alongside mortality outcomes in the same UK Biobank population. Its findings reinforced the roughly seven-hour duration signal and added that sleep continuity and timing also matter for death risk, though the study did not directly measure biological ageing clocks. Together, these three analyses form a chain: self-reported sleep duration maps to slower biological ageing, device-measured sleep duration maps to lower mortality, and both converge on the same narrow window.
On the public-health side, NCHS Data Brief No. 559 documented the prevalence of short sleep among U.S. adults using 2024 survey data, with demographic breakdowns showing that significant portions of the population sleep fewer than seven hours. That gap between what the science now shows and what people actually do is where the practical stakes sit.
Gaps in the evidence and what to watch next
The strongest limitation is one the studies themselves acknowledge: the UK Biobank cohort skews healthier and wealthier than the general population. How well the seven-hour finding applies to people with chronic illness, shift-work schedules, or lower socioeconomic status is not yet clear. The institutional cohort description notes this representativeness caveat without providing quantitative adjustment factors.
A second gap is causal direction. The U-shaped association between sleep and ageing does not prove that moving someone from five hours to seven will slow their biological clocks. People who naturally sleep seven hours may differ in genetics, stress exposure, or health behaviors in ways the studies cannot fully control for. The hypothesis that shifting sleep duration to seven hours through low-burden interventions, such as consistent bedtimes or reduced screen exposure, would produce measurable ageing-clock benefits has not been tested in a randomized trial. Until that trial exists, the data remain observational, however large and consistent.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
